147 related articles for article (PubMed ID: 16957418)
1. The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies.
Di Luigi L; Sottili M; Antinozzi C; Vannelli GB; Romanelli F; Riccieri V; Valesini G; Lenzi A; Crescioli C
PLoS One; 2013; 8(10):e77745. PubMed ID: 24204948
[TBL] [Abstract][Full Text] [Related]
2. D-hormone and its significance for function of prostate gland (literature review and personal observations).
Brechka NM; Bondarenko VO; Shcherbak OV; Korenieva YM
Wiad Lek; 2024; 77(1):135-143. PubMed ID: 38431818
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases.
Yang S; Li A; Wang J; Liu J; Han Y; Zhang W; Li YC; Zhang H
Curr Med Chem; 2018; 25(27):3256-3271. PubMed ID: 29446731
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions.
Ben-Eltriki M; Deb S; Guns ES
J Cancer; 2016; 7(4):391-407. PubMed ID: 26918053
[TBL] [Abstract][Full Text] [Related]
5. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
6. Benign prostatic hyperplasia: a new metabolic disease?
Vignozzi L; Rastrelli G; Corona G; Gacci M; Forti G; Maggi M
J Endocrinol Invest; 2014 Apr; 37(4):313-22. PubMed ID: 24458832
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D metabolism and action in the prostate: implications for health and disease.
Swami S; Krishnan AV; Feldman D
Mol Cell Endocrinol; 2011 Dec; 347(1-2):61-9. PubMed ID: 21664249
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment options for benign prostatic obstruction.
Parsons BA; Hashim H
Curr Urol Rep; 2011 Aug; 12(4):247-54. PubMed ID: 21475952
[TBL] [Abstract][Full Text] [Related]
9. Nutraceuticals in Prostate Disease: The Urologist's Role.
Curtis Nickel J; Shoskes D; Roehrborn CG; Moyad M
Rev Urol; 2008; 10(3):192-206. PubMed ID: 18836556
[TBL] [Abstract][Full Text] [Related]
10. Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
Brawer MK; Makarov DV; Partin AW; Roehrborn CG; Nickel JC; Lu SH; Yoshimura N; Chancellor MB; Assimos DG
Rev Urol; 2008; 10(2):136-56. PubMed ID: 18660856
[No Abstract] [Full Text] [Related]
11. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol).
Adorini L; Penna G; Amuchastegui S; Cossetti C; Aquilano F; Mariani R; Fibbi B; Morelli A; Uskokovic M; Colli E; Maggi M
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):689-93. PubMed ID: 17241782
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
Adorini L; Penna G; Fibbi B; Maggi M
Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
[TBL] [Abstract][Full Text] [Related]
14. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation.
Comeglio P; Chavalmane AK; Fibbi B; Filippi S; Marchetta M; Marini M; Morelli A; Penna G; Vignozzi L; Vannelli GB; Adorini L; Maggi M
J Endocrinol Invest; 2010 Nov; 33(10):730-8. PubMed ID: 20386089
[TBL] [Abstract][Full Text] [Related]
15. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
[TBL] [Abstract][Full Text] [Related]
16. Human bladder as a novel target for vitamin D receptor ligands.
Crescioli C; Morelli A; Adorini L; Ferruzzi P; Luconi M; Vannelli GB; Marini M; Gelmini S; Fibbi B; Donati S; Villari D; Forti G; Colli E; Andersson KE; Maggi M
J Clin Endocrinol Metab; 2005 Feb; 90(2):962-72. PubMed ID: 15572423
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
